Table 1.

Cell Cycle distribution of MCF-7 cells treated with 2ME/BE-3-3-3

Treatments	G1 Phase	S Phase	G2/M Phase
Control	67.2 ± 3.06	15.8 ± 2	12.8 ± 1.3
E2	55.9 ± 1.9#	22.2 ± 0.5#	15.3 ± 1.3
200 nM 2ME	60.25 ± 1.26	20.25 ± 0.6	14.2 ± 0.9
500 nM 2ME	61.4 ± 1.36	19.7 ± 0.7	14.2 ± 0.9
1000 nM 2ME	63.7 ± 1.8*	16.9 ± 1.2	12.7 ± 0.7
2.5 μM BE-3-3-3	69.1 ± 2.5**	14.6 ± 1.8**	12.2 ± 0.4
5 μM BE-3-3-3	72.9 ± 2.1**	11.7 ± 1.4**	11.6 ± 0.8
200 nM 2ME + 2.5 μM BE-3-3-3	69.8 ± 1.9**	13.6 ± 1.9**	11.1 ± 0.2
500 nM 2ME + 2.5 μM BE-3-3-3	68.9 ± 1.2**	12.8 ± 1.6**	11.6 ± 0.4
1000 nM 2ME + 2.5 μM BE-3-3-3	67.8 ± 0.7**	11.9 ± 1.3**	11.6 ± 0.8
200 nM 2ME + 5 μM BE-3-3-3	73.3 ± 1.06**	11.2 ± 1.0**	11.2 ± 1
500 nM 2ME + 5 μM BE-3-3-3	76 ± 1.3**	9.25 ± 1.2**	10.5 ± 0.8
1000 nM 2ME + 5 μM BE-3-3-3	76.4 ± 1.06**	7.8 ± 1.1**	10 ± 0.7

All samples except the control also contained 10 nM E₂. Cells were treated for 72 h with appropriate concentrations of E₂ , 2ME and BE-3-3-3 with re-dosing at 48 h. Total number of cells will also include a sub-G1 fraction accounting for 5 to 10% of the cells.

^#Indicates statistical significance compared to the control (P < 0.05).

^*Indicates statistical significance compared to E₂-treated samples (P < 0.05).

^**Indicates statistical significance compared to E₂-treated samples (P < 0.01). Data are mean ± SE from three separate experiments.